UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.

One-year survival rates for patients receiving heart, liver and lung transplants at UCSF Medical Center exceed national averages at statistically significant levels, according to new data compiled by the Scientific Registry of Transplant Recipients (SRTR).

Heart surgeons at Johns Hopkins have evidence to support further tightening rather than easing of standards used to designate hospitals that are best at performing heart transplants.

Texas Children’s Hospital has been named the national lead center for a 12-hospital, 36-month clinical trial of the German-manufactured pediatric heart pump called Berlin Heart EXCOR® Pediatric Ventricular Assist Device (VAD).

Heart surgeons at Johns Hopkins say people who need heart transplants can largely avoid transplant failure due to elevated blood pressure in their lungs with the help of proper drug treatment.

ABO-incompatible heart transplantation (heart transplantation among non-compatible blood groups) can be safely performed in infants a year old or younger, researchers reported at the American Heart Association’s Scientific Sessions 2007.

Central nervous system infections develop infrequently following heart transplants but are a significant predictor of death, according to an article posted online today that will appear in the December 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.

Geron Corporation today reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.

American doctors are starting a dramatic experiment this month to try to save patients dying from congestive heart failure by temporarily resting their hearts, then boosting them with a drug long abused for bodybuilding.

Protected by its own nutrients and blood supply, a beating heart supported by an investigational organ preservation device was successfully transplanted into a 47-year-old man with congestive heart failure and pulmonary hypertension on Sunday, April 8.

A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies. Mayo researchers will report their findings on April 26 at The International Society for Heart & Lung Transplantation Annual Meeting and Scientific Session in San Francisco.